PHARMACEUTICAL 2023

Monopar Therapeutics
Rank 234 of 471

Monopar Therapeutics



PHARMACEUTICAL 2023

Monopar Therapeutics
Rank 234 of 471

Monopar Therapeutics

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points.The greatest weakness of Monopar Therapeutics is the variable Net Income, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 16% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	13,166
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,129
Liabilities, Non-Current	8.4
Other Assets	61
Other Compr. Net Income	12
Other Expenses	0
Other Liabilities	0
Other Net Income	21
Other Revenues	0
Property and Equipment	0
Research and Development	7,592
Selling, General and Administrative Expense	2,945

Output Variable	Value in 1000 USD
Assets	13,227
Liabilities	3,137
Expenses	10,537
Revenues	0
Stockholders Equity	10,090
Net Income	-10,516
Comprehensive Net Income	-10,510
BaseVar	13,467
ECR before LimitedLiability	140%
Economic Capital Ratio	261%